Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is used primarily to treat obsessive-compulsive disorder, although in some countries it is also approved to treat depression. It also potently inhibits CYP1A2 and CYP2C19, moderately inhibits CYP2C9, CYP2D6 and CYP3A4.[1][2] It is the only achiral clinically-used second-generation monoamine reuptake inhibitor (which is a generalized class including SSRIs, SNRIs, NRI, NDRI, etc.).
↑Hemeryck, A; Belpaire, FM (February 2002). "Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.". Current Drug Metabolism3 (1): 13–37. PMID11876575. doi:10.2174/1389200023338017.